CNX Therapeutics Announces CFO Transition: Olga Lund to depart, Claire Masterson Joins as new CFO

London, July 3 2024: - CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a focus on improving access to essential medicines, today announced that Olga Lund will be stepping down from her role as Chief Financial Officer to take a career break and spend more time with her family. Claire Masterson, an experienced financial executive, will succeed Ms. Lund as CFO, effective July 1, 2024.

Over the course of her three years as CFO, tenure, Ms. Lund played a pivotal role in CNX Therapeutics' financial strategy and growth, overseeing significant acquisitions and partnerships that expanded the company's presence to over 40 countries worldwide.

Reflecting on her time at CNX Therapeutics, Olga Lund said: "My journey with CNX Therapeutics has been an incredible and deeply fulfilling experience spanning nearly two decades. From the early days of carving out CNX to my recent role as CFO, I've had the privilege of witnessing and contributing to our remarkable growth and success.

“Over the past three years as CFO, I've worked alongside a dedicated team to strengthen our financial foundations and drive our strategic goals. I am immensely proud of what we have achieved together and grateful for the friendships and memories I've made along the way. CNX will always hold a special place in my heart, and I am excited to see what the future holds for this extraordinary company."

Guy Clark, CEO of CNX Therapeutics, commented on the transition: "Olga has been an invaluable member of our leadership team, instrumental in driving our financial success and strategic expansion. As one of the founding architects of CNX Therapeutics, her financial acumen and dedication have been critical in positioning CNX for long-term growth. While we will miss her presence, we fully support her decision to prioritise family at this time and are deeply grateful for her contribution."

CNX Therapeutics is pleased to announce that Claire Masterson has joined the company as its new CFO, effective July 1, 2024. Claire brings extensive experience in financial management, having worked in digital healthcare, venture/PE-backed businesses, and Alternative Investments. Her expertise and leadership will be invaluable as CNX continues to grow and innovate. Ms. Lund will remain with the company at the beginning of July to ensure a smooth transition.

CNX Therapeutics’ new CFO Claire Masterson commented: "I am thrilled to join CNX Therapeutics at this exciting time in the company's journey. I look forward to working with Guy and the team to build on the strong foundation Olga has established and drive continued growth."

CNX Therapeutics was acquired by Inflexion Private Equity, a leading mid-market private equity firm, in 2021.

About CNX Therapeutics

CNX Therapeutics is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 40 countries worldwide, both directly and through strategic partnerships.

CNX is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and hospital injectable products, which is committed to the highest standards of ethics and sustainability. CNX has a pioneering approach to Environment, Social and Governance (ESG), which forms a key part of its mission. For more information on CNX Therapeutics, please visit: www.cnx-therapeutics.com